We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
No sample left behind.
- Abstract
The article focuses on the increased need of advance genome sequencing and mass cytometry technologies, which can provide insight into T cell receptor (TCR), B cell receptor (BCR) and ensure proper handling of samples of patients undergoing immune therapies. It discusses the financial problems faced by immune profiling clinical trials, and states that Insurance firms fund only those immune profiling assays, which have been approved by the U.S. Food and Drug Administration (FDA).
- Subjects
NUCLEOTIDE sequence; T cell receptors; B cell receptors; GENETIC techniques; UNITED States. Food &; Drug Administration; EQUIPMENT &; supplies
- Publication
Nature Biotechnology, 2015, Vol 33, Issue 10, p1010
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt.3381